Clinical trials
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma clinical trials
Below are recruiting gastric cancer or gastroesophageal junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 1,148 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06223230Recruiting
Supportive care trial for advanced digestive cancers
This trial tests if adding nutrition counseling, psychological support, and better nausea control to standard cancer treatment can help people with advanced digestive cancers live longer and feel better.
Wuhan, HubeiAges 18–75 - NCT06251115Recruiting
Study of QY-1-T for advanced HBV-related liver cancer
This study tests a new treatment called QY-1-T for people with advanced liver cancer related to hepatitis B. It is for patients who have already tried other standard treatments and have a certain genetic marker (HLA-A*11:01).
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06258642Recruiting
Irinotecan liposome plus anlotinib for SCLC after first chemo
This trial tests a combination of two drugs—irinotecan liposome (a chemotherapy) and anlotinib (a targeted therapy)—as a second treatment for small cell lung cancer that returned quickly after initial chemo. The goal is to see if this combo can work better than standard options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06269211RecruitingPhase 2
Immunotherapy before surgery for EGFR-mutated lung cancer
This trial tests whether giving an immunotherapy drug (toripalimab) before surgery can help people with a specific type of lung cancer (EGFR-mutated, PD-L1 positive) that can be removed. The goal is to see if it improves treatment results compared to surgery alone.
Guangzhou, GuangdongAges 18 years+ - NCT06293703Recruiting
Leg length ratio and weight loss after gastric bypass
This study looks at how the length of different parts of your small intestine affects weight loss after Roux-en-Y gastric bypass surgery. It may help doctors tailor the surgery for better results.
Cleveland, OhioAges 18–70 - NCT06310902Recruiting
Single-cell study for resectable pancreatic cancer patients
This trial uses a special technique called single-cell sequencing to study pancreatic cancer cells from patients whose tumors can be surgically removed or are on the edge of being removable. Participation may help researchers understand the disease better and could guide future treatments.
Fuzhou, FujianAges 18–75 - NCT06350318RecruitingPhase 2
Rituximab and Zanubrutinib for slow-growing B-cell lymphomas
This trial tests a combination of two targeted drugs (rituximab and zanubrutinib) for people with slow-growing B-cell lymphomas like marginal zone or follicular lymphoma. It may be a good option if you haven't had treatment for your lymphoma before and your disease needs therapy to manage symptoms.
Tampa, FloridaAges 18 years+ - NCT06406634RecruitingPhase 2
Cadonilimab, Lenvatinib, and HAIC for Unresectable Liver Cancer
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Changsha, HunanAges 18–75 - NCT06434363RecruitingPhase 1/Phase 2
Cell therapy plus tafasitamab for autoimmune diseases
This trial tests a new cell therapy (AD-PluReceptor) combined with the drug tafasitamab for people with certain autoimmune diseases like systemic sclerosis, lupus, or chronic graft-versus-host disease. It aims to see if this treatment can help when standard therapies have failed.
Houston, TexasAges 18 years+ - NCT06464926Recruiting
Electrical stimulation for chronic nausea and vomiting
This study tests a device that sends mild electrical pulses to your stomach to help with chronic nausea and vomiting. It is for people who have had nausea for over 6 months, have normal stomach emptying, and have not found relief from standard medications.
Scottsdale, ArizonaAges 18 years+ - NCT06482801RecruitingPhase 2
Immunotherapy combo for newly treated liver cancer
This trial tests a combination of immunotherapy drugs given directly into the liver’s blood supply as a first treatment for liver cancer. It aims to see if this approach can shrink tumors and improve outcomes for people with relatively preserved liver function.
GuangzhouAges 18–75 - NCT06489158Recruiting
Breath test for women with suspicious breast ultrasound findings
This study collects breath samples from women with suspicious breast ultrasound findings (BI-RADS 4) before surgery to see if certain chemicals in the breath can help identify cancer. If you are scheduled for surgery soon, your breath may help researchers find a new way to screen for breast cancer.
Beijing, Beijing MunicipalityAges 18–80 - NCT06492408RecruitingPhase 2
Immunotherapy before surgery for liver cancer
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
Guanzhou, GuangdongAges 18–75 - NCT06554613RecruitingPhase 2
Olanzapine with first-line immunotherapy for advanced lung cancer trial
This trial tests whether adding the drug olanzapine to standard first-line immunotherapy (with or without chemotherapy) can help people with advanced lung cancer that does not have an EGFR mutation. It aims to improve treatment outcomes and quality of life.
Nanchang, JiangxiAges 18–75 - NCT06567015RecruitingPhase 1/Phase 2
STX-241 for advanced EGFR-mutant lung cancer after TKI failure
This trial tests an experimental drug called STX-241 for people with a specific type of advanced lung cancer (NSCLC) that has an EGFR mutation (exon 19 deletion or L858R) and has stopped responding to a third-generation EGFR inhibitor (like osimertinib). The drug aims to target a new mutation, C797X, that sometimes appears after osimertinib stops working.
Nashville, TennesseeAges 18 years+ - NCT06567353Recruiting
Heat-based immunotherapy for breast cancer liver metastases
This trial tests a new treatment that uses heat to target liver tumors and boost the immune system. It is for women with breast cancer that has spread to the liver who cannot have or do not want surgery.
ShanghaiAges 18–75 - NCT07528716RecruitingPhase 3
AI-guided treatment for HER2-positive breast cancer
This trial tests whether an artificial intelligence model can help doctors choose the best targeted therapy before surgery for HER2-positive breast cancer (a type of breast cancer with a protein called HER2). The goal is to improve how well the treatment works and reduce side effects.
ShanghaiAges 18–75 - NCT07459309Recruiting
Combination treatment for liver cancer for people who can't have surgery
This trial tests a new combination treatment that uses heat (ablation) and other therapies to destroy liver tumors. It's for people who cannot have surgery or choose not to, and whose tumor is a specific size.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07620951RecruitingPhase 1
How Your Body Processes an Experimental Cancer Drug
This is an early-stage study testing how a new cancer medication (zorifertinib) moves through and leaves a healthy male body. Researchers use a special radioactive marker to track the drug so they can understand how it works and how safe it is.
Suzhou, JiangsuAges 18–45 - NCT06621173RecruitingEarly Phase 1
Gene therapy for advanced colorectal cancer (dMMR/MSI-H)
This trial tests a new gene therapy (HNF4α SrRNA) given through a vein for people with advanced colorectal cancer that has a specific genetic marker (dMMR or MSI-H). It's for those who have already tried standard treatments without success or couldn't take them.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06671119Recruiting
Weight regain treatment after sleeve gastrectomy with mucosal ablation
This trial tests a procedure to help people who have regained weight after a sleeve gastrectomy. It uses a special technique to treat the stomach lining and may help you lose weight again.
Cary, North CarolinaAges 22–60 - NCT05127824RecruitingPhase 2
Kidney cancer vaccine made from your own immune cells
This Phase 2 study tests a personalized kidney cancer vaccine made from your own immune cells. It aims to help your immune system recognize and attack clear cell kidney cancer after surgery, potentially lowering the chance of the cancer coming back.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06726642Recruiting
Blood test study for people with inherited cancer risk
This study looks for DNA fragments in blood of people with certain inherited cancer syndromes. It may help find cancer earlier or guide better monitoring. You would give blood samples every 4 months (if in the experimental group).
Vancouver, British ColumbiaAges Up to 90 years - NCT06746623Recruiting
Non-endoscopic screening for Barrett's in veterans without reflux
This trial tests a new, non-endoscopic screening method for Barrett's esophagus (a condition that can lead to cancer) in veterans who do not have chronic acid reflux. It aims to find early signs of the condition using a simple swallowable device, potentially avoiding the need for a traditional endoscopy.
Cleveland, OhioAges 40–85
Hear when a new Gastric Cancer or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gastric cancer or gastroesophageal junction adenocarcinoma?
- Yes. Clin2 currently lists 1,148 recruiting gastric cancer or gastroesophageal junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric cancer or gastroesophageal junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric cancer or gastroesophageal junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal-junction Cancer
- Metastatic Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.